This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
December 2023 marked a historic moment: the FDA simultaneously approved two gene-based therapies for sickle cell disease — exagamglogene autotemcel (Casgevy, the first CRISPR-based medicine ever approved) and lovotibeglogene autotemcel (Lyfgenia). Together, these one-time treatments represent a potential functional cure. In 2026, attention is turning to access, affordability, long-term follow-up, and whether next-generation approaches can simplify the intensive conditioning regimen that currently limits who can safely receive these therapies.
Casgevy: The First CRISPR Medicine
Exagamglogene autotemcel (exa-cel, Casgevy, Vertex/CRISPR Therapeutics) uses CRISPR-Cas9 gene editing to reactivate fetal hemoglobin (HbF) in the patient's own hematopoietic stem cells. The target is BCL11A — a transcriptional repressor that silences the gamma-globin genes responsible for HbF production. Normally, HbF is switched off in early infancy; reactivating it produces hemoglobin that does not sickle, effectively treating both sickle cell disease and beta-thalassemia.
In the CLIMB SCD-121 trial, 29 of 29 patients with severe sickle cell disease who had follow-up data were free of severe vaso-occlusive crises (pain crises) for at least 12 months after treatment. The CLIMB THAL-111 trial in transfusion-dependent beta-thalassemia showed 39 of 42 evaluable patients became transfusion-independent. FDA approval was granted in December 2023 for patients 12 years and older with recurrent vaso-occlusive crises. The list price is approximately $2.2 million.
Lyfgenia: Gene Addition Therapy
Lovotibeglogene autotemcel (lovo-cel, Lyfgenia, bluebird bio) uses a lentiviral vector to insert a functional anti-sickling beta-globin gene (betaA-T87Q) into the patient's own hematopoietic stem cells. Unlike CRISPR editing, gene addition does not require cutting the genome — the therapeutic gene is delivered as a separate copy.
In the HGB-206 Phase 1/2 trial, 88% of evaluable patients achieved complete resolution of severe vaso-occlusive crises for at least 12 months. Notably, two patients in the lovo-cel program developed hematologic malignancies (acute myeloid leukemia), though investigation did not find direct causation from vector insertion — it appears related to pre-existing clonal hematopoiesis in the stem cells. A long-term safety registry is tracking all lovo-cel recipients, and the FDA requires 15 years of follow-up. The list price is approximately $3.1 million, making it the most expensive drug ever approved at launch.
Access, Affordability, and Next-Generation Approaches
Both gene therapies require myeloablative conditioning — high-dose busulfan chemotherapy to eliminate existing bone marrow cells — which is associated with infertility, infection risk, and prolonged hospitalization (typically 3–6 months of intensive care). This, combined with the manufacturing complexity (stem cell collection, editing, quality testing, reinfusion at specialized centers) and cost, means access is severely limited — estimated at fewer than 50–100 patients treated per year in 2025 in the US.
Next-generation approaches aim to reduce conditioning intensity. Non-genotoxic conditioning regimens — using antibody-drug conjugates that deplete HSCs without chemotherapy — are in Phase 1/2 trials and could eventually enable outpatient gene therapy administration. In vivo gene editing approaches (delivering CRISPR components via lipid nanoparticles directly to the patient's HSCs without ex vivo manipulation) are in preclinical and early clinical development at Beam Therapeutics, Prime Medicine, and others, potentially reducing cost and complexity dramatically.
Non-Gene Therapy Advances: Voxelotor and Crizanlizumab
For patients who are not candidates for gene therapy — due to age, organ damage, lack of specialized center access, or personal choice — several newer drug-based therapies have expanded the treatment landscape beyond hydroxyurea.
Voxelotor (Oxbryta) increases hemoglobin's oxygen affinity, preventing deoxygenation-induced sickling. It raised hemoglobin by 1.0–2.0 g/dL in the HOPE trial. However, bluebird bio withdrew voxelotor from the market in September 2024 citing commercial reasons, a significant setback for patients relying on it. Global access remains via expanded access programs.
Crizanlizumab (Adakveo) is a P-selectin inhibitor that reduces vaso-occlusive crises by blocking adhesion of sickled red cells to blood vessel walls. The SUSTAIN trial showed a 45.3% reduction in crisis rate. Novartis has faced challenges with variable real-world response data, and post-marketing studies are ongoing.
GBT601 and inclacumab are next-generation anti-sickling and anti-P-selectin agents in Phase 2 trials seeking to improve on voxelotor and crizanlizumab respectively.
Key Takeaways
- Casgevy (CRISPR-based) and Lyfgenia (lentiviral gene addition) are both FDA-approved one-time treatments offering functional cure in 88–100% of treated patients.
- Both require myeloablative conditioning and cost $2–3 million; access is currently limited to fewer than 100 patients per year in the US.
- Non-genotoxic conditioning and in vivo editing are in development to lower the barrier to gene-based therapy.
- Voxelotor was withdrawn from the US market in 2024; crizanlizumab remains available but with ongoing post-marketing evaluation.
- Next-generation small molecules (GBT601, inclacumab) are in Phase 2, targeting improved efficacy and safety over their predecessors.